PSYCHOPHARMACOLOGY

THURSDAY-SUNDAY, OCTOBER 22-25, 2015 Westin Copley Place • 10 Huntington Ave., Boston, MA

COURSE DIRECTORS: Jerrold F. Rosenbaum, MD Maurizio Fava, MD Psychiatrist-in-Chief Director, Division of Clinical Research of Massachusetts General Hospital the MGH Research Institute Stanley Cobb Professor of Psychiatry Executive Vice Chair, Department of Psychiatry Harvard Medical School Executive Director, MGH Clinical Trials Network and Institute Massachusetts General Hospital Slater Family Professor of Psychiatry Harvard Medical School

Massachusetts General Hospital MGHCME.org Psychiatry Academy PSYCHOPHARMACOLOGY Thursday–sunday • OcTOber 22-25, 2015 WesTin cOpley place • 10 hunTinTOn ae, bOsTOn, Ma

WELCOME Welcome to the Massachusetts General Hospital Psychiatry Academy’s 39th Annual Psychopharmacology Course.

This course highlights the latest research findings in psychopharmacology and their clinical applications across the spectrum of psychiatric disorders, including, anxiety, ADHD, depression, bipolar disorder, eating disorders, OCD, psychosis, PTSD, substance abuse, and more.

TARGET AUDIENCE This program is intended for psychiatrists, primary care and family practice physicians, psychologists, nursing professionals, and social workers.

COMPLIMENTARY BREAKFAST AND COFFEE BREAKS Complimentary breakfast and coffee breaks will be available to course participants. Please note: lunch and dinner are not provided and are on your own.

EVALUATION FORMS/CME/CEU CERTIFICATES Every participant needs to complete the activity evaluation online to claim CME/CEU credits for this course. Please refer to the Evaluation and CME Information document in this syllabus for more information. We strongly encourage you to complete the evaluation, even if you do not require a certificate. Your comments are important to us as we plan future programs. The link to claim credit is as follows: www.mghcme.org/psychopharm

QUESTIONS Opportunity for questions will be provided at the end of each module during the panel discussion. Please write your questions on the index cards provided. Cards will be collected during the last 15 minutes of the lecture prior to the start of the panel discussion. Experience has shown that this method is preferable to that of spontaneous questions.

COPYRIGHT The course materials and PowerPoint presentations are copyright protected by Massachusetts General Hospital, Department of Psychiatry, Division of Postgraduate Education, the faculty members and the appropriate authors. Videotaping and audiotaping are not allowed. Thank you for your cooperation.

CELLULAR TELEPHONES & PAGERS During the lectures, we ask that you turn your cell phones and pagers to vibrate or off. We also ask that you do not talk on your cell phones inside the meeting room. Thank you for your cooperation.

CONTACT INFORMATION For questions or comments, please contact MGH Psychiatry Academy member services at 866-644-7792 or [email protected]

Massachusetts General Hospital MGHCME.org Psychiatry Academy LEARNING OBJECTIVES At the end of this educational activity, participants should be able to: . Identify rational, evidence-based pharmacologic and non-pharmacologic therapies for patients with unipolar, bipolar, treatment-resistant, and post-partum depression. . Assess obstacles to maintenance of long-term recovery and the liability issues associated with psychopharmacology. . Discuss diagnostic and evidenced-based treatment strategies for pediatric onset mood disorders. . Compare the neurobiology and evidence-based treatment approaches to addiction, anxiety, schizophrenia, and mood disorders. . Review the course and treatment of psychiatric disorders during pregnancy and menopause. . Recognize psychosocial issues and evidence-based treatment modalities for eating and sleep disorders. . Analyze drug interactions and the pharmacotherapy of adult ADHD and geriatric disorders.

ACCREDITATION This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of McLean Hospital and Massachusetts General Hospital. McLean Hospital is accredited by the ACCME to provide continuing medical education for physicians.

McLean Hospital designates this live activity for a maximum of 31.25 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

PSYCHOLOGISTS The Massachusetts General Hospital Department of Psychiatry is approved by the American Psychological Association to sponsor continuing education (CE) for psychologists. The Massachusetts General Hospital Department of Psychiatry maintains responsibility for this program and its content. This offering meets the criteria for 31.25 Continuing Education (CE) credits for psychologists.

REGISTERED NURSES This program meets the requirements of the Massachusetts Board of Registration in Nursing (244 CMR 5.00) for 31.25 contact hours of nursing continuing education credit. Advance practice nurses, please note: Educational activities which meet the requirements of the ACCME (such as this activity) count towards 50% of the nursing requirement for ANCC accreditation.

SOCIAL WORKERS This program has been approved for 30.5 Social Work Continuing Education hours for relicensure, in accordance with 258 CMR. Collaborative of NASW and the Boston College and Simmons Schools of Social Work Authorization Number D 71097.

RISK MANAGEMENT (**Sessions qualify for risk management credit)

Physicians: 1.5 credits meet the criteria of the Massachusetts Board of Registration in Medicine for risk management study.

Other CE Licenses: Other Providers can claim a Participation Certificate upon successful completion of this course. Participation Certificates will specify the title, location, type of activity, date of activity, and number of AMA PRA Category 1 Credits™ associated with the activity. Providers should check with their regulatory agencies to determine ways in which AMA PRA Category 1 Credits™ may or may not fulfill continuing education requirements. Providers should also consider saving copies of brochures, agenda, and other supporting documents.

Massachusetts General Hospital MGHCME.org Psychiatry Academy AGENDA

Thursday, October 22, 2015

4:00 – 8:00PM Neuromodulation 2015: State of the Art THIS IS A TICKETED EVENT, DINNER SERVED

Friday, October 23, 2015

7:00 – 8:00AM Registration &Continental Breakfast

8:00 – 8:15AM Welcome Maurizio Fava, MD

8:15 – 8:30AM Introduction and Overview Jerrold F. Rosenbaum, MD

MODULE TOPIC – MOOD DISORDERS

8:30– 9:15AM Bipolar Depression Andrew A. Nierenberg, MD

9:15 – 10:00AM Bipolar Long Term Management Roy H. Perlis, MD, MSc

10:00 – 10:15AM Coffee Break

10:15 – 11:00AM Treatment Resistant Depression Maurizio Fava, MD

11:00 – 12:00PM Panel Discussion Moderator: Jerrold F. Rosenbaum, MD Panelists: Andrew A. Nierenberg, MD; Roy H. Perlis, MD, MSc; Maurizio Fava, MD

12:00 – 1:00PM Lunch (onyourown)

MODULE TOPIC – ANXIETY/OCD

1:00 – 1:45PM OCD Michael A. Jenike, MD

1:45 – 2:30PM PTSD Naomi M. Simon, MD, MSc

2:30 – 3:15PM Anxiety Disorders and Treatments Kerry J. Ressler, MD, PhD

3:15 – 3:30PM Coffee Break

3:30 – 4:15PM Obsessive-Compulsive Related Disorders Lisa M. Zakhary, MD, PhD

Massachusetts General Hospital MGHCME.org Psychiatry Academy 4:15 – 5:00PM Panel Discussion Moderator: Michael A. Jenike, MD Panelists: Kerry J. Ressler, MD, PhD; Lisa M. Zakhary, MD, PhD; Naomi M. Simon, MD, MSc

5:00 – 6:30PM Dinner (onyourown)

Friday, October 23, 2015: Evening Seminars

6:30 – 7:30PM Friday Evening Seminars (please pick two): 7:30 – 8:30PM Seminars will begin at 6:30 PM and will repeat at 7:30 PM.

Natural Medications for Psychiatric Disorders Albert S. Yeung, MD, ScD (Adams/Baltic, 7th Floor)

Suicide Theodore A. Stern, MD (St. George A-B, 3rd Floor)

The Neurobiology of Addiction Jodi Gilman, PhD (St. George C, 3rd Floor)

Psychopharmacology of Sleep Disorders Matt T. Bianchi, MD, PhD, MMSc (America Ballroom, 4th Floor)

The Neurobiology of Mood and Psychotic Disorders Dost Öngür, MD, PhD (Empire, 7th Floor)

Cognitive-Behavioral Therapy to Augment Psychopharmalogical Therapy Michael W. Otto, PhD (St. George D, 3rd Floor)

Massachusetts General Hospital Psychiatry Academy MGHCME.org Saturday, October 24, 2015

7:00 – 8:00AM Continental Breakfast

8:00 – 8:10AM Welcoming Remarks David H. Rubin, MD

MODULE TOPIC – PSYCHOSIS

8:10 – 8:55AM First-Episode Psychosis and Schizophrenia Oliver Freudenreich, MD, FAPM

8:55 – 9:30AM Drug Interactions Jonathan E. Alpert, MD, PhD

9:30 – 9:45AM Coffee Break

9:45 – 10:30AM Management of Side-Effects of Antipsychotics David C. Henderson, MD

10:30 – 11:30AM Panel Discussion Moderator: David H. Rubin, MD Panelists: Oliver Freudenreich, MD, FAPM; David C. Henderson, MD; Jonathan E. Alpert, MD, PhD

11:30 – 12:30PM Lunch (onyourown)

MODULE TOPIC – NEW THERAPIES

12:30 – 1:30PM Stimulation and/or Surgical Approaches to Psychiatric Illness Darin D. Dougherty, MD, MMSc

1:30 – 2:30PM New Treatments for Bipolar Disorder Roy H. Perlis, MD, MSc

2:30 – 2:45PM Coffee Break

2:45 – 3:45PM New Treatments for Depression George I. Papakostas, MD

3:45 – 4:30PM New Antipsychotics David C. Henderson, MD

4:30 – 5:15PM Panel Discussion Moderator: David C. Henderson, MD Panelists: Roy H. Perlis, MD, MSc; George I. Papakostas, MD

5:15 – 6:30PM Dinner (onyourown)

Massachusetts General Hospital MGHCME.org Psychiatry Academy Saturday, October 24, 2015: Evening Seminars

6:30 – 7:30PM Saturday Evening Seminars (please pick one): Seminars will begin at 6:30PM and do not repeat.

Violence and Risk Assessment in Clinical Practice (90 minutes)** Ronald Schouten, MD, JD, Sgt. Frederick Cabral, FBI Supervisory Special Agent (America Ballroom, 4th Floor)

Traumatic Brain Injury: A Neuropsychiatric Perspective Kaloyan S. Tanev, MD (Independence A-B, 4th Floor)

Illuminating the Black Box: Antidepressants, Youth and Suicide David H. Rubin, MD (St. George A-B, 3rd Floor)

Massachusetts General Hospital Psychiatry Academy MGHCME.org Sunday, October 25, 2015

7:00 – 7:45AM Continental Breakfast

7:45 – 8:00AM Welcoming Remarks and Review David H. Rubin, MD

MODULE TOPIC – ADDICTION

8:00 – 9:00AM Tobacco and Cocaine A. Eden Evins, MD, MPH

9:00 – 10:00AM Alcohol and Opiates Domenic A. Ciraulo, MD

10:00 – 10:15AM Coffee Break

MODULE TOPIC – WOMEN’S HEALTH

10:15 – 11:15AM Pregnancy Lee S. Cohen, MD

11:15 – 12:15PM Post-Partum Mood Disorders Marlene P. Freeman, MD

12:15 – 1:15PM Lunch (onyourown)

MODULE TOPIC – ACROSS THE LIFESPAN

1:15 – 2:15PM Pediatric Bipolar Disorder and Mood Disorders Janet Wozniak, MD

2:15 – 3:15PM ADHD Joseph Biederman, MD

3:15 – 3:30PM Coffee Break

3:30 – 4:30PM Rapid Treatments for Psychiatric Disorders Cristina Cusin, MD

4:30 – 5:30PM Geriatrics Feyza Marouf, MD

5:30PM Adjourn

Thank you for attending! We hope to see you next year! 40th Annual Psychopharmacology Conference Boston, MA | October 21 -23, 2016

Massachusetts General Hospital MGHCME.org Psychiatry Academy FACULTY

Course Directors: Jerrold F. Rosenbaum, MD Maurizio Fava, MD Psychiatrist-in-Chief, Massachusetts General Hospital, Stanley Director, Division of Clinical Research of the MGH Research Cobb Professor of Psychiatry, Harvard Medical School Institute, Executive Vice Chair, Department of Psychiatry, Executive Director, MGH Clinical Trials Network and Institute, Massachusetts General Hospital, Slater Family Professor of Psychiatry, Harvard Medical School Faculty: Jonathan E. Alpert, MD, PhD Cristina Cusin, MD Associate Chief of Psychiatry for Clinical Services, Director, Staff Psychiatrist, Depression Clinical and Research Program, Depression Clinical and Research Program, Massachusetts Massachusetts General Hospital, Assistant Professor, Harvard General Hospital, Joyce R. Tedlow Associate Professor of Medical School Psychiatry, Harvard Medical School Darin D. Dougherty, MD, MMSc Matt T. Bianchi, MD, PhD, MMSc Director,DivisionofNeurotherapeutics,Departmentof Chief,DivisionofSleepMedicine,Director,SleepLaboratory, Psychiatry, Massachusetts General Hospital, Associate Massachusetts General Hospital Professor of Psychiatry, Harvard Medical School

Joseph Biederman, MD A. Eden Evins, MD, MPH Chief,ClinicalandResearchProgramsinPediatric Director,CenterforAddictionMedicine,MassachusettsGeneral Psychopharmacology and Adult ADHD, Director, Bressler Hospital, William Cox Family Associate Professor of Psychiatry Program for Autism Spectrum Disorders, Massachusetts in the Field of Addiction Medicine, Harvard Medical School General Hospital, Professor of Psychiatry, Harvard Medical School FBI Supervisory Special Agent

Frederick Cabral Marlene P. Freeman, MD Community Relations Unit Sergeant, Cambridge Police Associate Director, Perinatal and Reproductive Psychiatry Department Clinical Research Program, Massachusetts General Hospital, Associate Professor of Psychiatry, Harvard Medical School Joan A. Camprodon, MD, PhD, MPH Director, Transcranial Magnetic Stimulation (TMS) Clinical Oliver Freudenreich, MD, FAPM Service,Director,LaboratoryforNeuropsychiatryand Medical Director, MGH Schizophrenia Program, Massachusetts Neuromodulation, Director, Translational Research, Division of General Hospital, Associate Professor of Psychiatry, Harvard Neurotherapeutics,AttendingPhysician,DivisionofBehavioral Medical School Neurology, Department of Neurology, Attending Physician, Division of Neuropsychiatry, Department of Psychiatry, Jodi Gilman, Ph.D. Massachusetts General Hospital Assistant Professor, Harvard Medical School Center for Addiction Medicine Domenic A. Ciraulo, MD Massachusetts General Hospital DirectorofAlcoholPharmacotherapyResearch,Centerfor David C. Henderson, MD Addiction Medicine, Department of Psychiatry, Massachusetts General Hospital Director, Schizophrenia Clinical and Research Program, Director,ChesterM.Pierce,M.D.DivisionofGlobalPsychiatry, Massachusetts General Hospital, Associate Professor of Lee S. Cohen, MD Psychiatry, Harvard Medical School, Associate Professor of Director, Center for Women’s Mental Health, Perinatal Epidemiology, Harvard School of Public Health and Reproductive Psychiatry Clinical Research Program, Massachusetts General Hospital, Edmund and Carroll Carpenter Michael E. Henry, MD Professor of Psychiatry, Harvard Medical School Director, Somatic Therapy, Medical Director, Bipolar Clinic and Research Program, Massachusetts General Hospital

Massachusetts General Hospital MGHCME.org Psychiatry Academy Michael A. Jenike, MD Ronald Schouten, MD, JD Founder, OCD Clinic, Massachusetts General Hospital, Medical Director, Law & Psychiatry Service, Massachusetts General Director, Massachusetts General Hospital/McLean Hospital OCD Hospital, Associate Professor of Psychiatry, Harvard Medical Institute, Professor of Psychiatry, Harvard Medical School School

Feyza Marouf, MD Naomi M. Simon, MD, MSc Assistant Psychiatrist, MGH Geriatric Outpatient Clinic, MGH Site Chief Medical Officer, Red Sox Foundation and Massachusetts Director, Partners Healthcare Geriatric Psychiatry Fellowship General Hospital Home Base Program, Director, Center for Anxiety & Traumatic Stress Disorders, Director, Complicated Grief Program, Massachusetts General Hospital, Professor of Andrew A. Nierenberg, MD Psychiatry, Harvard Medical School Thomas P. Hackett, MD, Endowed Chair in Psychiatry, Director, Bipolar Clinic and Research Program, Associate Director, Depression Clinical and Research Program, Massachusetts General Theodore A. Stern, MD Hospital, Professor of Psychiatry, Harvard Medical School Chief, Avery D. Weisman Psychiatric Consultation Service, Director, Office for Clinical Careers, Massachusetts General Hospital, Ned H. Cassem Professor of Psychiatry in the field of Dost Öngür, MD, PhD Psychosomatic Medicine/Consultation, Harvard Medical School Chief, Psychotic Disorders Division, McLean Hospital, Associate Professor of Psychiatry, Harvard Medical School Kaloyan S. Tanev, MD DirectorofClinical NeuropsychiatryResearch,Massachusetts Michael W. Otto, PhD General Hospital, Assistant Professor of Psychiatry, Harvard Director, Translational Research Program, Department of Medical School Psychology, Boston University Janet Wozniak, MD George I. Papakostas, MD Director, Quality and Safety, Department of Psychiatry, Director, Scientific Director, Clinical Trials Network and Institute, Child and Adolescent Outpatient Service, Director, Pediatric Massachusetts General Hospital Bipolar Disorder Clinical and Research Program, Massachusetts General Hospital, Associate Professor of Psychiatry, Harvard Roy H. Perlis, MD, MSc Medical School Director, Center for Experimental Drugs and Diagnostics, DepartmentofPsychiatry,Director,CenterforHumanGenetic Albert S. Yeung, MD, ScD Research, Massachusetts General Hospital, Associate Professor of Director of Primary Care Research, Depression Clinical and Psychiatry, Harvard Medical School Research Program, Massachusetts General Hospital, Associate Professor of Psychiatry, Harvard Medical School Kerry J. Ressler, MD, PhD Chief Scientific Officer, James and Patricia Poitras Chair in Lisa M. Zakhary, MD, PhD Psychiatry, Chief, Division of Depression & Anxiety Disorders, Staff Psychiatrist, OCD and Related Disorders Program, Primary McLean Hospital, Professor of Psychiatry, Harvard Medical School Care Psychiatry, Massachusetts General Hospital, Instructor in Psychiatry, Harvard Medical School David H. Rubin, MD Director of Child and Adolescent Psychiatry, Residency Training, Director, Postgraduate Medical Education, Massachusetts General Hospital

Massachusetts General Hospital MGHCME.org Psychiatry Academy FACULTY DISCLOSURE STATEMENTS

In accord with the disclosure policy of McLean Hospital as well as guidelines set forth by the Accreditation Council on Continuing Medical Education, speakers have been asked to disclose any relationship they have to companies producing pharmaceuticals, medical equipment, devices, etc. that might be germane to the content of their lectures. Such disclosure is not intended to suggest or condone bias in any presentation, but is elicited to provide participants with information that might be of potential importance to their evaluation of a given talk. In addition, faculty have been asked to describe any “off label” uses of pharmaceutical products and devices.

1. The following speakers and/or planners and/or their spouses/ partners have reported no relevant financial relationship with a commercial interest:

Planners: Jane Pimental, MPH David H. Rubin, MD (Reviewer/Speaker)

Speakers: Frederick Cabral Joan A. Camprodon, MD, PhD, MPH Domenic A. Ciraulo, MD Cristina Cusin, MD FBI Supervisory Special Agent Jodi Gilman, PhD Michael A. Jenike, MD Feyza Marouf, MD Dost Öngür, MD, PhD Ronald Schouten, MD, JD Kaloyan S. Tanev, MD Albert S. Yeung, MD, ScD Lisa M. Zakhary, MD, PhD 2. The following speakers and/or planners and/or their spouses/ partners have reported relevant financial relationships with commercial interests:

Jonathan E. Alpert, MD, PhD Speaker’s Honoraria: American Society of Clinical Psychopharmacology, American Psychiatric Association, Janssen, Nevada Psychiatric Association, North Shore Medical Center, Psicofarma, Reed Medical Education, University of Louisville Royalties: Belvoir Publishing, Marcel Dekker, Institut la Conference Hippocrate Consultant fees: PamLab LLC, Luye Pharmaceuticals Research support: Abbott Labs, Alkermes, Aspect Medical Systems, Astra-Zeneca, Bristol-Myers Squibb, Cephalon, Eli Lilly & Co., Forest Pharmaceuticals, GlaxoSmithKline, J&J Pharmaceuticals, Lichtswer Pharma, Novartis, Organon, PamLab LLC, Pharmavite, Roche Laboratories, Solvay Pharma, Sanofi/Synthelabo, Wyeth- Ayerst

Matt T. Bianchi, MD, PhD, MMSc Funding: MGH Neurology Department, Harvard Clinical Investigator Fellowship (‘09-11), CIMIT Young Clinician Award (‘11-13), Harvard Catalyst KL-2 (‘11-13), Milton Foundation (‘14-15), MGH-MIT Grand Challenge (‘14-15), Department of Defense (‘15-’16) Patent Pending: Rest Devices Advisory Board: Foramis Travel Funds: Servier Research: Insomnisolv, MC10 Consultant: GrandRounds, Insomnisolv, MC10 Dr. Bianchi also provides Expert Testimony

Massachusetts General Hospital MGHCME.org Psychiatry Academy Joseph Biederman, MD Research Support: DOD, FDA, AACAP , Alcobra, Forest Research Institute, Ironshore, Lundbeck, Magceutics Inc., Merck, PamLab, Pfizer, Shire Pharmaceuticals Inc., SPRITES, Sunovion, Vaya Pharma/Enzymotec, and NIH. Royalties paid to the Department of Psychiatry at MGH, for a copyrighted ADHD rating scale used for ADHD diagnoses: Ingenix, Prophase, Shire, Bracket Global, Sunovion, and Theravance Patents: US Patent Application (Provisional Number #61/233,686) through MGH corporate licensing, on a method to prevent stimulant abuse.

Lee S. Cohen, MD Research Support: National Pregnancy Registry for Atypical Antipsychotics: AstraZeneca; Bristol-Myers Squibb/Otsuka; Ortho-McNeil Janssen; Sunovion Pharmaceuticals, Inc.; Other research support: Cephalon, Inc.; National Institute on Aging; National Institutes of Health; National Institute of Mental Health; Takeda/Lundbeck Advisory/Consulting: JDS Therapeutics LLC

Darin D. Dougherty, MD, MMSc Research Support: Cyberonics, Medtronic, Eli Lilly, Roche Honoraria: Insys, Johnson & Johnson

A. Eden Evins, MD, MPH Research Support (to institution): Forum Pharmaceuticals, Pfizer Inc. Advisory Board: Reckitt Benckizer

Maurizio Fava, MD Advisory Board/Consultant: Abbott Laboratories; Affectis Pharmaceuticals AG; Alkermes, Inc.; Amarin Pharma Inc.; Aspect Medical Systems; AstraZeneca; Auspex Pharmaceuticals; Avanir Pharmaceuticals; AXSOME Therapeutics; Bayer AG; Best Practice Project Management, Inc.; BioMarin Pharmaceuticals, Inc.; Biovail Corporation; BrainCells Inc; Bristol-Myers Squibb; CeNeRx BioPharma; Cephalon, Inc.; Cerecor; CNS Response, Inc.; Compellis Pharmaceuticals; Cypress Pharmaceutical, Inc.; DiagnoSearch Life Sciences (P) Ltd.; Dinippon Sumitomo Pharma Co. Inc.; Dov Pharmaceuticals, Inc.; Edgemont Pharmaceuticals, Inc.; Eisai Inc.; Eli Lilly and Company; EnVivo Pharmaceuticals, Inc.; ePharmaSolutions; EPIX Pharmaceuticals, Inc.; Euthymics Bioscience, Inc.; Fabre-Kramer Pharmaceuticals, Inc.; Forest Pharmaceuticals, Inc.; Forum Pharmaceuticals; GenOmind, LLC; GlaxoSmithKline; Grunenthal GmbH; i3 Innovus/Ingenis; Janssen Pharmaceutica; Jazz Pharmaceuticals, Inc.; Johnson & Johnson Pharmaceutical Research & Development, LLC; Knoll Pharmaceuticals Corp.; Labopharm Inc.; Lorex Pharmaceuticals; Lundbeck Inc.; MedAvante, Inc.; Merck & Co., Inc.; MSI Methylation Sciences, Inc.; Naurex, Inc.; Nestle Health Sciences; Neuralstem, Inc.; Neuronetics, Inc.; NextWave Pharmaceuticals; Novartis AG;Nutrition 21; Orexigen Therapeutics, Inc.; Organon Pharmaceuticals; Otsuka Pharmaceuticals; Pamlab, LLC.; Pfizer Inc.; PharmaStar; Pharmavite® LLC.; PharmoRx Therapeutics; Precision Human Biolaboratory; Prexa Pharmaceuticals, Inc.; PPD; Puretech Ventures; PsychoGenics; Psylin Neurosciences, Inc.; RCT Logic, LLC ( formerly Clinical Trials Solutions, LLC); Rexahn Pharmaceuticals, Inc.; Ridge Diagnostics, Inc.; Roche; Sanofi- Aventis US LLC.; Sepracor Inc.; Servier Laboratories; Schering-Plough Corporation; Solvay Pharmaceuticals, Inc.; Somaxon Pharmaceuticals, Inc.; Somerset Pharmaceuticals, Inc.; Sunovion Pharmaceuticals; Supernus Pharmaceuticals, Inc.; Synthelabo; Takeda Pharmaceutical Company Limited; Tal Medical, Inc.; Tetragenex Pharmaceuticals, Inc.; TransForm Pharmaceuticals, Inc.; Transcept Pharmaceuticals, Inc.; Vanda Pharmaceuticals, Inc. Speaking/Publishing: Adamed, Co; Advanced Meeting Partners; American Psychiatric Association; American Society of Clinical Psychopharmacology; AstraZeneca; Belvoir Media Group; Boehringer Ingelheim GmbH; Bristol-Myers Squibb; Cephalon, Inc.; CME Institute/Physicians Postgraduate Press, Inc.; Eli Lilly and Company; Forest Pharmaceuticals, Inc.; GlaxoSmithKline; Imedex, LLC; MGH Psychiatry Academy/Primedia; MGH Psychiatry Academy/Reed Elsevier; Novartis AG; Organon Pharmaceuticals; Pfizer Inc.; PharmaStar; United BioSource,Corp.; Wyeth-Ayerst Laboratories. Research Support: Abbot Laboratories; Alkermes, Inc.; American Cyanamid;Aspect Medical Systems;

Massachusetts General Hospital Psychiatry Academy MGHCME.org AstraZeneca; Avanir Pharmaceuticals; BioResearch; BrainCells Inc.; Bristol-Myers Squibb; CeNeRx BioPharma; Cephalon; Clintara, LLC; Covance; Covidien; Eli Lilly and Company;EnVivo Pharmaceuticals, Inc.; Euthymics Bioscience, Inc.; Forest Pharmaceuticals, Inc.; Ganeden Biotech, Inc.; GlaxoSmithKline; Harvard Clinical Research Institute; Hoffman-LaRoche; Icon Clinical Research; i3 Innovus/Ingenix; Janssen R&D, LLC; Jed Foundation; Johnson & Johnson Pharmaceutical Research & Development; Lichtwer Pharma GmbH; Lorex Pharmaceuticals; Lundbeck Inc.; MedAvante; Methylation Sciences Inc; National Alliance for Research on Schizophrenia & Depression (NARSAD); National Center for Complementary and Alternative Medicine (NCCAM); National Institute of Drug Abuse (NIDA); National Institute of Mental Health (NIMH); Neuralstem, Inc.; Novartis AG; Organon Pharmaceuticals; PamLab, LLC.; Pfizer Inc.; Pharmacia-Upjohn; Pharmaceutical Research Associates., Inc.; Pharmavite® LLC;PharmoRx Therapeutics; Photothera; Reckitt Benckiser; Roche Pharmaceuticals; RCT Logic, LLC (formerly Clinical Trials Solutions, LLC); Sanofi-Aventis US LLC; Shire; Solvay Pharmaceuticals, Inc.; Stanley Medical Research Institute (SMRI); Synthelabo; Wyeth-Ayerst Laboratories Stock/Other Financial Options: Equity Holdings: Compellis; PsyBrain, Inc. Royalty/patent, other income: Patents for Sequential Parallel Comparison Design (SPCD), licensed by MGH to Pharmaceutical Product Development, LLC (PPD); and patent application for a combination of Ketamine plus Scopolamine in Major Depressive Disorder (MDD), licensed by MGH to Biohaven. Copyright for the MGH Cognitive & Physical Functioning Questionnaire (CPFQ), Sexual Functioning Inventory (SFI), Antidepressant Treatment Response Questionnaire (ATRQ), Discontinuation-Emergent Signs & Symptoms (DESS), Symptoms of Depression Questionnaire (SDQ), and SAFER; Lippincott, Williams & Wilkins; Wolkers Kluwer; World Scientific Publishing Co. Pte.Ltd.

Marlene P. Freeman, MD Research Funding (investigator initiated studies): Takeda Advisory Boards: Takeda, Sunovion, JDS Therapeutics CME/Honorarium for Medical Editing: GOED newsletter

Oliver Freudenreich, MD, FAPM Research Grant: Psychogenics, Forum Honoraria: Global Medical Education, Med-IQ, Oakstone Medical Education Consultant: Optimal Medicine, Beacon Health Strategies Royalties: UpToDate

David C. Henderson, MD Research Grant: Forum Pharmaceuticals, Norvartis Speaker Fee: Global Psychiatry CME, Mclean Hospital Advisory Board: Reckitt Benckiser

Michael E. Henry, MD Research Grant: Forest Pharmaceuticals Spouse Salary: Roche Pharmaceuticals

Andrew A. Nierenberg, MD Consultant: Abbott Laboratories, Astra Zeneca, Basilea, BrainCells Inc., Bristol-Myers Squibb, Cephalon, Clintara, Corcept, Eli Lilly & Co., Forest, Genaissance, Genentech, GlaxoSmithKline, Innapharma, Janssen Pharmaceutica, Jazz Pharmaceuticals, Lundbeck, Medavante, Merck, Novartis, PamLabs, PGx Health, Pfizer, Roche, Sepracor, Schering-Plough, Shire, Somerset, Sunovion, Takeda, Targacept, Teva Stockholder: Appliance Computing, Inc. (MindSite); Brain Cells, Inc., Medavante Grant Support: AFSP, AHRQ, Bristol-Myers Squibb, Cederroth, Cyberonics, Forest Pharmaceuticals, GlaxoSmithKline, Janssen Pharmaceutica, Lichtwer Pharma, Eli Lilly, NARSAD, NIMH, PCORI, Pfizer, Shire, Stanley Foundation, Takeda, Wyeth-Ayerst Other Income: MBL Publishing for past services as Editor-in-chief of CNS Spectrums; Slack Inc. for services as Associate Editor of Psychiatric Annals; Editorial Board, Mind Mood Memory, Belvior Publications Patents and Copyrights: Copyright joint ownership with MGH for Structured Clinical Interview for MADRS and Clinical Positive Affect Scale

Massachusetts General Hospital MGHCME.org Psychiatry Academy Honoraria: ADURS, Brain and Behavior Foundation Colvin Prize, University of :Pisa, University of Wisconsin at Madison, University Texas Southwest at Dallas, Health New England and Harold Grinspoon Charitable Foundation and Eli Lilly and AstraZeneca, American Society for Clinical Psychopharmacology and Zucker Hillside Hospital and Forest and Janssen, Brandeis University, International Society for Bipolar Disorder

Michael W. Otto, PhD Grant Support: NIMH, NIDA Royalties: Oxford University Press, Routledge

George I. Papakostas, MD Consultant: Abbott Laboratories, AstraZeneca PLC, Avanir Pharmaceuticals, Brainsway Ltd., Bristol-Myers Squibb Co., Cephalon Inc., Dey Pharma, L.P., Eli Lilly Co., Genentech, Inc., GlaxoSmithKline, Evotec AG, H. Lundbeck A/S, Inflabloc Pharmaceuticals, Janssen Global Services LLC, Jazz Pharmaceuticals, Johnson & Johnson Companies, Novartis Pharma AG, One Carbon Therapeutics, Inc., Otsuka Pharmaceuticals, PAMLAB LLC, Pfizer Inc., Pierre Fabre Laboratories, Ridge Diagnostics (formerly known as Precision Human Biolaboratories), Shire Pharmaceuticals, Sunovion Pharmaceuticals, Takeda Pharmaceutical Company LTD, Theracos, Inc., and Wyeth, Inc. Honoraria: Abbott Laboratories, Astra Zeneca PLC, Avanir Pharmaceuticals, Bristol-Myers Squibb Co., Brainsway Ltd., Cephalon Inc., Dey Pharma, L.P., Eli Lilly Co., Evotec AG, Forest Pharmaceuticals, GlaxoSmithKline,InflablocPharmaceuticals,JazzPharmaceuticals,H.LundbeckA/S,MedichemPharmaceuticals, Inc., Novartis Pharma AG, Otsuka Pharmaceuticals, PAMLAB LLC, Pfizer, Pierre Fabre Laboratories, Ridge Diagnostics, Shire Pharmaceuticals, Sunovion Pharmaceuticals, Takeda Pharmaceutical Company LTD, Theracos, Inc., Titan Pharmaceuticals, and Wyeth Inc. Research Support: AstraZeneca PLC, Bristol-Myers Squibb Co., Forest Pharmaceuticals, the National Institute of Mental Health, PAMLAB LLC, Pfizer Inc., Ridge Diagnostics (formerly known as Precision Human Biolaboratories), Sunovion Pharmaceuticals, and Theracos, Inc. Speaker’s Bureau: Dr. Papakostas has served (not currently) on the speaker’s bureau for Bristol-Myers Squibb Co. and Pfizer, Inc.

Roy H. Perlis, MD, MSc Scientific Advisory Board: Psybrain, Genomind Consultation: Genomind, RID Ventures, Perfect Health Advisor: Perfect Health

Jerrold F. Rosenbaum, MD Equity Interest: Medavante Equity Interest: Founder: PsyBrain

Kerry J. Ressler, MD, PhD Founding Member: Extinction Pharmaceuticals/ Therapade Technologies (received no equity or income from this relationship within the last 3 years). Patents: D-cycloserine and psychotherapy, targeting PACAP for extinction, targeting tachykinin 2 for prevention of fear, targeting angiotensin to improve extinction of fear. Funding: NIMH, HHMI, NARSAD, Burroughs Wellcome Foundation

Massachusetts General Hospital Psychiatry Academy MGHCME.org Naomi M. Simon, MD, MSc Research Grants: American Foundation for Suicide Prevention, Department of Defense, Highland Street Foundation, NIH Speaking/CME/Consulting: Pfizer Pharmaceuticals Equity (Spouse): Dandreon, G Zero, Gatekeeper

Theodore A. Stern, MD Salary: Academy of Psychosomatic Medicine (Editor in Chief Psychosomatics) Royalties: Elsevier Honoraria: Psychiatric Annals

Janet Wozniak, MD Research funding: Merck/Schering-Plough Consultation Fees (Spouse): Associated Professional Sleep Societies, Gerson Lerman Group, Summer Street Partners, UCB, Cantor Colburn Royalties (Spouse): Cambridge University Press

RESOLUTION OF CONFLICT OF INTEREST (COI) McLean Hospital has implemented a process to resolve COI for each CME activity. In order to help ensure content objectivity, independence, fair balance and ensure that the content is aligned with the interest of the public, McLean Hospital has resolved the conflict by External Content Review.

* “Something of value” refers to an equity position, receipt of royalties, consultantship, funding by a research grant, receiving honoraria for educational services elsewhere, or to any other relationship to a company that provides sufficient reason for disclosure, in keeping with the spirit of the stated policy.

Massachusetts General Hospital MGHCME.org Psychiatry Academy PSYCHOPHARMACOLOGY CURBSIDE CONSULTANTS SCHEDULE OCTOBER 22 - 25, 2015

FACULTY NAME TOPIC DAY AND TIME Andrew A. Nierenberg, MD Bipolar Disorder and Friday, October 23, 9:15am – 10:15am Depression Naomi M. Simon, MD, MSc Anxiety and PTSD Friday, October 23, 3:15pm – 4:15pm

Oliver Freudenreich, MD, FAPM Psychosis Saturday, October 24, 9:00am – 10:00am

John D. Matthews, MD Depression and Inpatient Saturday, October 24, 1:00pm – 2:00pm Psychiatry Theodore A. Stern, MD Consult Psychiatry Saturday, October 24, 4:00pm – 5:00pm

Marlene P. Freeman, MD Women’s Health Sunday, October 25, 10:15am – 11:15am

Lee S. Cohen, MD Women’s Mental Health Sunday, October 25, 11:15am – 12:15pm

Cristina Cusin, MD Rapid Treatments Sunday, October 25, 2:30pm – 3:30pm

Massachusetts General Hospital MGHCME.org Psychiatry Academy Massachusetts General Hospital MGHCME.org Psychiatry Academy Jodi Gilman, PhD

Matt T. Bianchi, MD, PhD, MMSc

Massachusetts General Hospital Psychiatry Academy MGHCME.org Massachusetts General Hospital MGHCME.org Psychiatry Academy Massachusetts General Hospital Psychiatry Academy MGHCME.org Massachusetts General Hospital MGHCME.org Psychiatry Academy Massachusetts General Hospital MGHCME.org Psychiatry Academy